Barnett Community Development Corporation, Jacksonville, Florida, and thereby engage in investing in corporations or projects designed primarily to promote community welfare, pursuant to § 225.28(b)(12) of the Board's Regulation Y; EquiCredit Corporation, Jacksonville, Florida, and its direct and indirect subsidiaries, and thereby engage in the activities of originating home equity and purchase money loans, acquiring such loans originated from third parties, and securitizing such loans in the secondary market, pursuant to § 225.28(b)(1) of the Board's Regulation Y, and in acting as principal, agent, or broker for credit related insurance, pursuant to § 225.28(b)(11) of the Board's Regulation Y; Equity/Protect Reinsurance Company, Jacksonville, Florida, and thereby engage in the activities of reinsuring credit related insurance policies sold to EquiCredit Corporation customers, pursuant to § 225.28(b)(11) of the Board's Regulation Y; and Honor Technologies, Inc., Maitland, Florida, and thereby engage in operating an electronic funds transfer network and in data processing and management consulting activities, pursuant to §§ 225.28(b)(9) and (b)(14), respectively of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, October 14, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–27636 Filed 10–17–97; 8:45 am]

BILLING CODE 6210–01–F

GENERAL SERVICES ADMINISTRATION

[GSA Bulletin FPMR D–245]

Public Buildings and Space

TO: Heads of Federal Agencies.

SUBJECT: Protecting Federal Employees and the Public From Exposure to Tobacco Smoke in the Federal Workplace.

1. *PURPOSE.* This bulletin announces the policy concerning the protection of Federal employees and the public from exposure to tobacco smoke in the Federal workplace.

2. *EXPIRATION DATE.* This bulletin contains information of a continuing nature and will remain in effect until canceled.

Background

a. On August 9, 1997, President Clinton signed Executive Order 13058, entitled ''Protecting Federal Employees and the Public From Exposure to Tobacco Smoke in the Federal Workplace,'' (62 FR 43451, August 13, 1997), to establish a smoke-free environment for Federal employees and members of the public visiting or using Federal facilities. The General Services Administration (GSA) is providing governmentwide policy guidance concerning the requirements of this Executive Order so that federal agencies may benefit from GSA's real property management expertise.

b. The policy previous to Executive Order 13058, enunciated in FPMR § 101–20.105–3, declared all GSA-controlled space non-smoking except where designated smoking areas are identified by agency heads. This Executive Order prohibits, with some exceptions, the smoking of tobacco products in all interior space owned, rented or leased by the executive branch of the Federal Government. GSA will amend FPMR § 101–20.105–3 in the near future to reflect the new policy in this Executive Order.

c. Unlike the previous policy, this Executive Order requires that designated smoking areas be enclosed and exhausted directly to the outside and away from air intake ducts, and maintained under negative pressure sufficient to contain tobacco smoke within the designated area. Agency officials must not require workers to enter such areas during business hours while smoking is ongoing.

Action

a. In accordance with Executive Order 13058, Federal agencies must prohibit the smoking of tobacco products in all interior space owned, rented, or leased by the executive branch of the Federal Government, and in any outdoor areas under executive branch control in front of air intake ducts.

b. The only exceptions are designated smoking areas; residential accommodations for persons voluntarily or involuntarily residing, on a temporary or long-term basis, in a building owned, leased, or rented by the Federal Government; portions of federally-owned buildings leased, rented, or otherwise provided (in their entirety) to nonfederal parties; and places of employment in the private sector or in other nonfederal governmental units that serve as the permanent or intermittent duty station of one or more federal employees.

c. The heads of Federal agencies may establish limited and narrow exceptions that are necessary to accomplish agency missions. Such exception must be in writing, approved by the agency head, and to the fullest extent possible provide protection of nonsmokers from exposure to environmental tobacco smoke. Authority to establish such exceptions may not be delegated.

d. The heads of Federal agencies must evaluate the need to restrict smoking at doorways and in courtyards under executive branch control in order to protect workers and visitors from environmental tobacco smoke, and may restrict smoking in these areas in light of this evaluation.

e. The heads of Federal agencies are encouraged to use existing authority to establish programs designed to help employees stop smoking.

f. The heads of Federal agencies must implement and ensure compliance with the policy set forth in this Executive Order no later than August 9, 1998. Prior to this date, the heads of Federal agencies must inform all employees and visitors to executive branch facilities about the requirements of this order, inform their employees of the health risks of exposure to environmental tobacco smoke, and undertake related activities as necessary.

Dated: October 9, 1997.

G. Martin Wagner,

Associate Administrator, Office of Governmentwide Policy.

[FR Doc. 97–27703 Filed 10–17–97; 8:45 am]

BILLING CODE 6820–23–P

GENERAL SERVICES ADMINISTRATION

Office of Transportation Audits; Stocking Change of a Standard Form

AGENCY: General Services Administration.

ACTION: Notice.

SUMMARY: The General Services Administration/Office of Transportation is changing the stocking of the following Standard form because of low use demand:

SF 362, U.S. Government Freight Loss/ Damage Claim

Since this form is not authorized for local reproduction, you can obtain the updated camera copy in three ways:

From the ''U.S. Government Management Policy CD–ROM'';

On the internet. Address: http://www.gsa.gov/forms; or

From CARM, Attn.: Barbara Williams, (202) 501–0581.

FOR FURTHER INFORMATION CONTACT: Transportation Audit Division, (202) 219–1494. This contact is for information on completing the form and interpreting the FPMR only.

DATES: Effective October 20, 1997.

Dated: October 1, 1997.

Barbara M. Williams,

Deputy Standard and Optional Forms Management Officer.

[FR Doc. 97–27648 Filed 10–17–97; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 94N–0227]

Nandlal G. Rana; Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) permanently debarring Mr. Nandlal G. Rana, 184 Parsonage Rd., Edison, NJ 08817, from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Rana was convicted of a felony under Federal law for conduct relating to the regulation of a drug product under the act. Mr. Rana failed to request a hearing and, therefore, has waived his opportunity for a hearing concerning this action.

EFFECTIVE DATE: October 20, 1997.

ADDRESSES: Application for termination of debarment to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Christine F. Rogers, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION:

I. Background

On October 5, 1993, the United States District Court for the District of Maryland entered judgment against Mr. Nandlal G. Rana for one count of obstructing an agency proceeding, a Federal felony under 18 U.S.C. 1505.

As a result of this conviction, FDA served Mr. Rana by certified mail on February 17, 1995, a notice proposing to permanently debar him from providing services in any capacity to a person that has an approved or pending drug product application, and offered him an opportunity for a hearing on the proposal. The proposal was based on a finding, under section 306(a)(2)(B) of the act (21 U.S.C. 335a(a)(2)(B)), that Mr. Rana was convicted of a felony under Federal law for conduct relating to the regulation of a drug product. Mr. Rana was provided 30 days to file objections and request a hearing. Mr. Rana did not request a hearing. His failure to request a hearing constitutes a waiver of his opportunity for a hearing and a waiver of any contentions concerning his debarment.

II. Findings and Order

Therefore, the Director, Center for Drug Evaluation and Research, under section 306(a)(2)(B) of the act, and under authority delegated to her (21 CFR 5.99), finds that Mr. Nandlal G. Rana has been convicted of a felony under Federal law for conduct relating to the regulation of a drug product.

As a result of the foregoing finding, Mr. Nandlal G. Rana is permanently debarred from providing services in any capacity to a person with an approved or pending drug product application under section 505, 507, 512, or 802 of the act (21 U.S.C. 355, 357, 360b, or 382), or under section 351 of the Public Health Service Act (42 U.S.C. 262), effective October 20, 1997 (sections 306(c)(1)(B) and (c)(2)(A)(ii) and 201(dd) of the act (21 U.S.C. 321(dd))). Any person with an approved or pending drug product application who knowingly uses the services of Mr. Rana, in any capacity, during his period of debarment, will be subject to civil money penalties (section 307(a)(6) of the act (21 U.S.C. 335b(a)(6))). If Mr. Rana, during his period of debarment, provides services in any capacity to a person with an approved or pending drug product application, he will be subject to civil money penalties (section 307(a)(7) of the act). In addition, FDA will not accept or review any abbreviated new drug applications submitted by or with the assistance of Mr. Rana during his period of debarment.

Any application by Mr. Rana for termination of debarment under section 306(d)(4) of the act should be identified with Docket No. 94N–0227 and sent to the Dockets Management Branch (address above). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: October 1, 1997.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 97–27693 Filed 10–17–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Cardiovascular and Renal Drugs Advisory Committee. This meeting was announced in the **Federal Register** of September 18, 1997. The amendment is being made to: Remove the second agenda item scheduled on October 23, 1997; add a closed session to the agenda scheduled on October 23, 1997; and provide a new location site for this closed session. There are no other changes. This amendment will be announced at the beginning of the open portion of the meeting.

FOR FURTHER INFORMATION CONTACT: Joan C. Standaert, Center for Drug Evaluation and Research (HFD–110), 419–259–6211, or Danyiel D'Antonio (HFD–21), 301–443–5455, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12533. Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of September 18, 1997 (62 FR 49015), FDA announced that a meeting of the Cardiovascular and Renal Drugs Advisory Committee would be held on October 23 and 24, 1997. This amendment is to provide an update to the information provided earlier pertaining to the October 23, 1997, meeting day. There are no changes for the October 24, 1997, meeting day. On page 49015, beginning in column 3, portions of the notice pertaining to the October 23, 1997, meeting day are amended to read as follows:

Location: October 23, 1997, 8:30 a.m. to 2 p.m., National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD.